The pattern of substitution is less complicated when low efficacy agonists such as nalbuphine and butorphanol are trained as discriminative stimuli. Under these conditions, both high and low efficacy agonists produce full substitution for nalbuphine or butorphanol, generally independent of the training dose (Walker and Young, 1993; Gerak and France, 1996; Picker et al., 1996) . Moreover, the discriminative stimulus effects of nalbuphine (Walker and Young, 1993; Gerak and France, 1996) , butorphanol (Picker et al., 1996) , and dezocine (Picker, 1997) are blocked by µ, but not κ or δ opioid receptor antagonists, indicating that the effects are mediated through µ opioid receptors.
When pigeons are trained to discriminate among morphine, nalbuphine, and saline in a three-choice discrimination procedure, low efficacy compounds such as butorphanol, nalorphine, and levallorphan produce predominantly nalbuphine-appropriate responding (Walker et al., 2001) . Low doses of morphine, fentanyl, etorphine, buprenorphine, and dezocine also produce nalbuphine-appropriate responding whereas high doses of these compounds produce morphine-appropriate responding.
A different pattern is observed in opioid-dependent subjects. Under these conditions, low efficacy agonists such as nalbuphine generally precipitate withdrawal or produce withdrawal-like stimulus effects. For example, nalbuphine precipitates JPET #58503 6 under some conditions of opioid dependence, nalbuphine produces effects similar to opioid antagonists such as naltrexone.
The present study uses a three choice discrimination procedure to examine further the discriminative stimulus effects of the low efficacy agonist nalbuphine in morphinetreated pigeons. The following questions are addressed: First, can pigeons be trained to discriminate among a low efficacy agonist, such as nalbuphine, a high efficacy agonist, such as morphine and saline under conditions of daily morphine treatment? Second, what patterns of substitution will a range of high and low efficacy agonists and opioid antagonists produce under these conditions? Finally, how are the discriminative stimulus effects of nalbuphine and morphine altered during morphine withdrawal?
JPET #58503 8 counted but had no programmed consequences. The number of responses required for food delivery was increased to 30 (fixed ratio FR30) over several experimental sessions.
Morphine, saline, and nalbuphine training sessions were conducted randomly with the restriction that a given training drug was not administered for more than two consecutive sessions. Training conditions continued until an individual pigeon met the following conditions: 1) the first 30 responses completed were made on the correct training key; 2) less than 60 responses were made before the first reinforcer; 3) the percentage of responses emitted on the appropriate key during the entire session was >80%; and 4) the above conditions were met for nine out of 12 consecutive days. In addition, the pigeon needed to meet criteria 1-3 for three saline training days, three nalbuphine training days, and three morphine training days. After initial testing criteria were met, tests were performed whenever pigeons met the above criteria for each of the three training conditions for three consecutive days.
Test sessions were conducted using a multiple-trial, cumulative-dosing procedure (Walker et al., 2001) . Each trial consisted of a 15-min pretreatment period and a testing component that ended after ten reinforcers or 5 min, whichever came first. During the testing component, completion of an FR30 on any key produced food. For cumulative dosing, the dose of drug administered before each trial increased the total dose by 0.25 to 1.0 log 10 unit. Each test consisted of five to eight trials. For repeated saline tests, an injection of saline was administered at the beginning of every trial for five trials. In the naltrexone and nalbuphine reversal tests, the training dose of morphine was administered to the pigeons and was followed by cumulative doses of naltrexone or nalbuphine. In the morphine withdrawal study, the daily 10 mg/kg morphine injection was replaced by This article has not been copyedited and formatted. The final version may differ from this version. saline and the pigeons were tested six hours later with saline. Following the saline injection, cumulative doses of morphine were tested. The following day, the morning morphine injections were reinstated.
At the end of the experiment, the morning morphine injection was replaced with saline for twenty-three consecutive days. Six hours later, on days 1, 3, 8, 15, 18 and 23, the pigeons were injected with saline again and placed into the experimental chambers for a single trial test. Fifteen minutes later, the three stimulus lights were illuminated for fifteen min and completion of an FR30 on any key produced food. Under similar testing conditions, the training doses of 10 mg/kg morphine and 1.0 mg/kg nalbuphine were tested on days 16 and 17 and 3.2 mg/kg morphine and 10 mg/kg nalbuphine were examined on days 19 and 22, respectively. On those days on which the pigeons were not tested, they received saline injections in the morning and 6 h later they were fed in their home cage.
Surgery.
To deliver drugs centrally, a permanent in-dwelling cannula (Plastic One, Inc., Roanoke, VA) was placed into the lateral ventricle of each pigeon with a stereotaxic instrument (Stoelting Co., Wood Dale, Illinois) and a Rezvin adapter (Karten and Hodos, 1967) using methods previously described (France et al., 1985; Jewett et al., 1996) . Briefly, each pigeon was anesthetized with 8 mg/kg of ketamine and 2.5-2.75 ml/kg of Chloropent (chloral hydrate and pentobarbital: Fort Dodge Laboratories, Fort Dodge, Iowa). After surgery, a removable 28 g dummy cannula was inserted into the guide cannula. Patency of each cannula was tested by injecting 17.2 µg of 2-amino-5-phosphonovalerate (Sigma, St. Louis, MO) and observing catalepsy (Koek et al., 1986) .
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S.E.M. is used to express variance. Data from pigeons responding less than 30 times during a trial were included in the response rate figures but not the discrimination figures.
The dose required to produce 50% drug-appropriate responding (ED 50 value), reduce drug-appropriate responding to 50% (ID 50 value), and reduce response rates to 50% (ED 50 value) and 95% C.L. were calculated by nonlinear regression analysis using unconstrained maximum and minimum values for the logistic equations (GraphPad Prism Version 3.0; San Diego, CA).
Drugs:
The following compounds were used: buprenorphine hydrochloride were generally prepared to deliver each injection in a volume of 0.1 to 0.7 ml per pigeon into the breast muscle. Doses are expressed as the forms listed above. Saline was injected in a volume of 1 ml/kg of b.wt. As observed in previous studies (Walker et al., 2001) , 10 mg/kg buprenorphine disrupted training performance for one to four weeks.
Therefore, higher doses of buprenorphine were not examined.
Nalbuphine and the peptides CTAP and DAMGO were administered i.c.v. using a cumulative-dosing procedure (Jewett et al., 1996) . For cumulative dosing, the drugs were dissolved in filtered sterile water and were prepared to deliver each injection in a volume 
Results
Substitution experiments with the training drugs. The morphine, nalbuphine, and saline discrimination was acquired by all seven pigeons in an average of 42 days with a range of 10 to 120 days. After the pigeons met testing criteria, cumulative doses of nalbuphine and morphine were administered. Low doses of nalbuphine produced salinekey responding and higher doses of nalbuphine produced >80% nalbuphine-key responding in all pigeons (figure 1, left panels; Table 1 ). Low doses of morphine produced saline-key responding and higher doses of morphine (10 mg/kg morphine or more) produced morphine-key responding in all pigeons (figure 1, right panels; Table 1 ).
Five trials of repeated saline injections produced predominantly >80% saline-key responding ( Table 1) . Doses of 100 mg/kg nalbuphine and morphine decreased response rates to 25% and 0% of saline control values, respectively. Doses of 32 and 100 mg/kg nalbuphine produced vomiting in three pigeons. ED 50 values and 95% C.L. are reported in Table 1 .
Substitution experiments with other compounds. Etorphine and fentanyl produced a pattern of substitution similar to morphine in that low and high doses of etorphine and fentanyl produced saline-and morphine-key responding, respectively.
Etorphine (figure 2, left panels) and fentanyl (figure 2, left middle panels) produced >80% morphine-key responding in most pigeons (Table 1) . Buprenorphine, dezocine (figure 2, right middle and right panels) and butorphanol (figure 3, left panels) produced a combination of saline-, nalbuphine-, and morphine-key responding in the morphinetreated pigeons (Table 1 ). The lower efficacy agonists nalorphine and levallorphan (Table 1 ). The κ agonists U50,488 and spiradoline, the delta agonist SNC80 and the nonopioid d-amphetamine produced predominantly saline-key responding (Table 1) . Nalbuphine (i.c.v.) and DAMGO (i.c.v.) produced 50-100% nalbuphine-or morphine-key responding, respectively, in four of the five pigeons tested.
All compounds with the exception of buprenorphine were examined at doses up to those that decreased rates of responding to less than 25% of saline control values (figures 1-3, bottom panels; Table 1 Single and daily morphine withdrawal experiments. When saline was substituted for the morning 10 mg/kg morphine injection, a saline injection six hours later produced approximately 80% nalbuphine-key responding. This nalbuphine-key responding was reversed by morphine (figure 4, right panels; Table 1 ). However, the potency of morphine was not altered in the absence of the morning morphine injection (Table 1) .
After the completion of the above experiments, the morning morphine injection was replaced with saline for twenty-three days and the pigeons were tested 6 h later on various days with saline, morphine, or nalbuphine ( 
Discussion
The data collected in this study indicate that the low efficacy µ agonist nalbuphine produces a unique pattern of stimulus effects in morphine-treated pigeons. Under these conditions, nalbuphine's discriminative effects are similar to those of the opioid antagonist, naltrexone, other low efficacy µ agonists, and the termination of daily morphine treatment.
Interestingly, substitution tests with high efficacy opioid agonists in the current studies revealed that the nalbuphine discriminative stimulus no longer reflects agonist actions in morphine-treated pigeons whereas the nalbuphine discriminative stimulus clearly reflects agonist actions in non-treated pigeons. For example, when non-treated pigeons are trained to discriminate a low dose of morphine from a high dose, high efficacy agonists produce responding on the key appropriate to a low-dose of morphine followed by responding on the key appropriate to a high-dose of morphine (Vanecek and Young, 1995) . Similarly, in non-treated pigeons trained to discriminate among morphine, nalbuphine, and saline, high efficacy agonists produce nalbuphine-key responding at low doses and morphine-key responding at higher doses (Walker et al., 2001 ). In contrast, data collected in the current study indicate that the high efficacy agonists, etorphine, morphine and fentanyl, do not produce nalbuphine-key responding at any dose in morphine-treated pigeons (figure 2). Instead, etorphine, fentanyl, and morphine produce a greater proportion of saline-key responding in morphine-treated pigeons as compared to non-treated pigeons (Walker et al., 2001 ). However, in both studies, etorphine, fentanyl and morphine produced morphine-key responding.
This article has not been copyedited and formatted. The final version may differ from this version. Similarly, butorphanol produced nalbuphine-key responding in greater than 75% of the non-treated pigeons, whereas butorphanol only produced nalbuphine-key responding in 25% of the morphine-treated pigeons (figure 3).
Interestingly, both nalorphine and levallorphan produced high levels of nalbuphine-key responding in both non-treated (Walker et al., 2001 ) and morphinetreated pigeons (present study) trained to discriminate among morphine, nalbuphine, and saline. In studies using two choice discriminations, nalorphine, levallorphan, and nalbuphine produce morphine-or fentanyl-appropriate responding as long as the training doses of morphine or fentanyl are low (Holtzman, 1985; Young et al., 1992; Zhang et al., 2000) . Similarly, nalorphine and levallorphan produce nalbuphine-appropriate (Walker and Young, 1993), butorphanol-appropriate (Picker et al., 1996) or dezocine-appropriate (Picker, 1996) responding when the discriminative stimuli are lower efficacy agonists (e.g., nalbuphine, butorphanol or dezocine). In morphine-treated pigeons, as in previous studies in non-treated pigeons and rats (Walker et al., 2001; Walker and Young, 1993) This article has not been copyedited and formatted. The final version may differ from this version. nalorphine and levallorphan retained the capacity to produce nalbuphine-key responding supporting the notion that these compounds all possess very low efficacy at µ opioid receptors.
The discriminative stimulus effects of the κ and δ agonists observed in morphinetreated pigeons in the present study were different from those observed previously in non-treated pigeons. The κ agonists, U50,488 and spiradoline, have been shown to produce some nalbuphine-appropriate responding in non-treated pigeons (Walker et al., 2001 ). However, in the current study, U50,488 and spiradoline did not produce nalbuphine-appropriate responding in pigeons treated daily with 10 mg/kg morphine and trained to discriminate a lower dose of nalbuphine. Similarly, the δ agonists failed to produce morphine-or nalbuphine-key responding under these conditions. Therefore, these observations provide further confirmation that neither the κ nor the δ opioid receptor play a prominent role in the morphine, nalbuphine, and saline discrimination in morphine-treated pigeons (Picker, 1994; Picker and Cook, 1997; 1998; France and Woods, 1993) .
The opioid antagonist naltrexone and the µ -selective peptide antagonist, CTAP, both produced nalbuphine-key responding in morphine-treated pigeons. Previous studies have shown that both nalbuphine and naltrexone can reverse the stimulus effects of morphine with potencies indicative of µ receptor blockade in morphine-treated subjects (France et al., 1990; Walker et al., 1996) . In the present study, pigeons respond on the nalbuphine key when saline injections were substituted for the morning morphine injections and increasing doses of morphine reversed responding on the nalbuphine key.
Both of these observations are in keeping with findings from other studies with
This article has not been copyedited and formatted. The final version may differ from this version. This observation demonstrates the similar degrees of morphine withdrawal between the two studies despite the fact that naltrexone or nalbuphine were trained as the discriminative stimuli in morphine-treated pigeons. Taken together, these data suggest that the discriminative stimulus effects of nalbuphine in morphine-treated pigeons parallel the discriminative stimulus effects of morphine withdrawal. Indeed, high doses of nalbuphine and naltrexone produced vomiting in some pigeons, a sign indicative of physical withdrawal.
Despite these similarities between naltrexone and nalbuphine, it should be noted that nalbuphine and naltrexone do not always produce similar stimulus effects. For example, naltrexone fails to substitute for nalbuphine and actually blocks the stimulus effects of nalbuphine in non-treated rats, pigeons, and rhesus monkeys trained to discriminate nalbuphine from saline (Gerak and France, 1996; Walker and Young, 1993; Walker et al., 2001 ). In morphine-treated pigeons trained to discriminate naltrexone from saline, nalbuphine produces approximately equal saline and naltrexone responding (France and Woods, 1990 ). Yet, in morphine-treated pigeons trained to discriminate between nalbuphine and saline, naltrexone substitutes fully for nalbuphine. This One feature of the nalbuphine discrimination in the present experiment, however, does not agree with the hypothesis that the nalbuphine stimulus represents the absence of morphine, whereas the saline stimulus represents a low dose of morphine. Studies in non-treated subjects have firmly established that high doses of nalbuphine evoke generalization with low dose morphine training stimuli (Morgan and Picker, 1998; Walker et al., 1996; Vanecek and Young, 1995; Young et al., 1992; Holtzman, 1985) .
Therefore, if the above hypothesis is true, as the nalbuphine dose is increased, responding should move from the nalbuphine key (proposed absence of drug stimuli) to the saline key (proposed low dose morphine stimulus). This did not occur, however. In contrast, increasing the dose of nalbuphine above the training dose produced only nalbuphine-key responding and occasional vomiting, suggesting the presence of a mild state of withdrawal. This outcome lends strong support to the alternate hypothesis that the nalbuphine stimulus comprised a withdrawal cue. It is possible that the discriminative stimulus effects of nalbuphine observed in the present study resemble the stimuli produced in models of acute dependence, in which animals are treated with morphine, and Holtzman, 2003) . This acute dependence model produces a pattern of discrimination that is unique from that observed when naltrexone is administered without morphine pretreatment. In the present study, 6 h pretreatment of morphine followed by nalbuphine may also produce a different set of interoceptive stimuli. Moreover, the data collected here suggest that these interoceptive stimuli are shared with opioid antagonists, low efficacy µ agonists, and single or daily morphine withdrawal.
This article has not been copyedited and formatted. The final version may differ from this version. Table 1 Discriminative stimulus and rate-decreasing effects for drugs tested in pigeons treated with 10 mg/kg morphine and trained to discriminate 1.0 mg/kg nalbuphine, 10 mg/kg morphine, and saline six hours later. Morning morphine injection was replaced with saline and the pigeons were tested with saline 6 h later. After the saline test, cumulative doses of morphine were studied. 
